ROUSSEAU JON B sold $7.6M of BTSG

ROUSSEAU JON B (See Remarks) sold 130,000 shares of BrightSpring Health Services, Inc. (BTSG) at $58.75 ($7.64M total) on 2026-06-05.

Original reporting
SEC EDGAR · ROUSSEAU JON B
Published Jun 5, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BTSG
Neutral
medium confidence
Mentioned
$BTSG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BTSGNeutralLow
01

Why it matters

The disclosure can modestly affect sentiment and short-term positioning, but it does not constitute new operational guidance, financial results, or deal/regulatory information.

02

Market read

Traders may use the sale as a sentiment input, but it is unlikely to be a standalone catalyst without corroborating fundamental news.

03

What to watch

Track whether additional insiders sell/buy around the same time and whether there are concurrent operational/regulatory updates not captured in this Form 4.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-06-05) as the sale; relevant for intraday/next-session sentiment checks.

Background

This is an SEC Form 4 insider transaction disclosure (officer/director selling issuer shares).

Company-level read

Ticker impact

$BTSGNeutralMedium confidence
Context

BrightSpring Health Services disclosed an officer/director open-market sale of 130,000 shares at $58.75 on 2026-06-05.

Expected impact

Likely limited/short-lived impact unless follow-on selling or additional disclosures emerge.

Evidence & confidence

Form 4 provides transaction details (size/price) but the filing does not indicate new company-specific news or a 10b5-1 plan.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing; the absence of a 10b5-1 plan does not automatically imply bearish fundamentals.

Key entities

  • BrightSpring Health Services, Inc.

    Subject of the Form 4 insider sale disclosed by an officer/director.

  • ROUSSEAU JON B

    Officer/director who sold 130,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BTSGHighAI 8/10

Guggenheim raises BrightSpring Health stock price target on growth

Guggenheim raised its price target on BrightSpring Health Services (BTSG) to $84 from $81, maintaining a Buy rating. The company reported strong Q3 2026 results, with revenue growth of 26% and earnings of $0.54 per share, exceeding expectations. Management expects 15-20% organic EBITDA growth in 2027. Analysts remain optimistic, with a consensus Strong Buy rating and targets ranging from $70 to $92.

$BTSGHighAI 8/10

UBS raises BrightSpring Health stock price target to $92 on growth outlook

UBS increased its price target for BrightSpring Health Services (BTSG) to $92 from $85, citing growth prospects in its Specialty Pharmacy and Infusion businesses. The stock has surged 102% over the past year. The company reported Q3 2026 earnings of $0.54 per share, beating estimates, and raised its 2026 revenue guidance to $15.9B-$16.125B. Goldman Sachs also raised its target to $90, highlighting strong growth.

$BTSGMed

BrightSpring Health Services Inc (BTSG) (Q3 2026) Earnings Call Highlights: Revenue Jumps

BrightSpring Health Services (BTSG) reported Q3 2026 revenue growth of 26%, but Home and Community Pharmacy revenue declined 6% due to IRA impact. CEO Jon Rousseau emphasized broad growth drivers and stability in LDD economics. The company expects IRA to remain a headwind with a $200M total impact. BTSG did not provide specific 2027 guidance, focusing on organic adjusted EBITDA growth. The CEO discussed M&A opportunities, primary care initiatives, and specialty script growth.